|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.97 USD | +6.49% |
|
+6.49% | -7.51% |
| 05-17 | Erasca Acquires 2 Exclusive Worldwide Licenses for Preclinical RAS Programs | MT |
| 05-17 | Erasca Prices $160 Million Common Stock Offering | MT |
Erasca, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 35.02 million compared to USD 33.2 million a year ago. Basic loss per share from continuing operations was USD 0.23 compared to USD 0.22 a year ago.
Diluted loss per share from continuing operations was USD 0.23 compared to USD 0.22 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -7.51% | 511M | |
| +33.63% | 50.93B | |
| -0.09% | 42.12B | |
| +49.62% | 42.05B | |
| -4.96% | 29.18B | |
| +11.18% | 26.02B | |
| -21.95% | 18.9B | |
| +8.61% | 13.21B | |
| +24.73% | 12.17B | |
| +28.31% | 12.16B |
ERASCA, INC. 
